NEU neuren pharmaceuticals limited

Ann: Neuren initiates development of NNZ-2591 to treat HIE, page-8

  1. 1,414 Posts.
    lightbulb Created with Sketch. 657
    OMG - Obviously very exciting to see another condition we are looking to treat but I am EXTREMELY interested in the nature of this condition.

    While it is considered Neurodevelopmental, it is not caused by a genetic mutation/abnormality, as are our current indications. Google suggests that it's a Neurodevelopmental condition, by virtue of the fact that it is caused by a brain injury that occurs, before, during or shortly after birth.

    Injury is obviously very different to genetic cause, and it does open up much broader questions about the scope of treatment for this wonderful drug.

    If it can treat a brain injury early in life, then surely the question has to be asked whether it can possibly treat a brain injury later in life - Concussion/TBI?? I acknowledge that they are not Orphan indications, but I think that is a problem for a potential acquirer to navigate.

    This really is very interesting!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$16.93
Change
-0.360(2.08%)
Mkt cap ! $2.133B
Open High Low Value Volume
$17.08 $17.67 $16.93 $6.897M 401.2K

Buyers (Bids)

No. Vol. Price($)
3 2660 $16.93
 

Sellers (Offers)

Price($) Vol. No.
$17.07 1994 2
View Market Depth
Last trade - 16.10pm 01/08/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.